M. Fletcher

Is pre-assessment for anti-TNF therapy in RA necessary in the UK? Analysis of DAS28 in six centres.

R. Cooper, L. Kay, J. Ledingham, 2007, Rheumatology.

Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAKâ•’906), a Novel Selective D₂/D₃ Receptor Antagonist: A Phase 1 Randomized, Placeboâ•’Controlled Singleâ•’ and Multipleâ•’Dose Escalation Study in Healthy Participants

B. Darpo, D. Combs, R. Whiting, 2021 .

A LOW DOSE REGIME OF 1α HYDROXYVITAMIN D3 IN THE MANAGEMENT OF SENILE OSTEOPOROSIS: A PILOT STUDY

I. Fogelman, W. Mcintosh, G. Beastall, 1980, Clinical endocrinology.

Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK‐906), a Novel Selective D2/D3 Receptor Antagonist: A Phase 1 Randomized, Placebo‐Controlled Single‐ and Multiple‐Dose Escalation Study in Healthy Participants

B. Darpo, D. Combs, R. Whiting, 2021, Clinical pharmacology in drug development.

First-time in-human study of VMD-928, an oral allosteric TrkA selective inhibitor targeting TrkA protein overexpression, in patients with solid tumors or lymphoma.

G. Giaccone, D. Hong, M. Cristea, 2021 .